AbCellera Biologics Inc. (ABCL) Revenue History
Annual and quarterly revenue from 2018 to present
ABCL Revenue Over Time (2018–2025)
ABCL Revenue Growth History
5 of 7 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- +31.5%
- FY2020 revenue growth
- +1907.9%
- FY2021 revenue growth
- +60.9%
- FY2022 revenue growth
- +29.4%
- FY2023 revenue growth
- -92.2%
- FY2024 revenue growth
- -24.2%
- FY2025 revenue growth
- +160.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.0M | -76.3% |
| Q1 2026 | $8.3M | +96.3% |
| Q4 2025 | $44.9M | +788.2% |
| Q3 2025 | $9.0M | +37.6% |
| Q2 2025 | $17.1M | +133.3% |
| Q1 2025 | $4.2M | -57.5% |
| Q4 2024 | $5.0M | -45.0% |
| Q3 2024 | $6.5M | -1.4% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
ABCL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ABCL Revenue Analysis (2018–2025)
Current Revenue & Growth
As of November 8, 2026, AbCellera Biologics Inc. (ABCL) generated trailing twelve-month (TTM) revenue of $66.2 million, reflecting significant decline in growth of -76.3% year-over-year. The most recent quarter (Q2 2026) recorded $4.0 million in revenue, down 51.3% sequentially.
Historical Growth Trajectory
ABCL's 5-year compound annual growth rate (CAGR) stands at -20.3%, indicating revenue contraction over this period. The 3-year CAGR of -46.3% is below the 5-year average, signalling a growth deceleration in recent years. AbCellera Biologics Inc.'s highest annual revenue of $485.4 million was recorded in 2022.
Revenue by Segment
ABCL's revenue is primarily driven by License (62%), Research Fees (36%), and Milestone Payments (1%). With over half of revenue concentrated in License, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including TWST (+19.2% YoY), RXRX (+56.7% YoY), and SDGR (+4.8% YoY) — ABCL has underperformed the peer group in revenue growth. Compare ABCL vs TWST →
ABCL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ABCLCurrent | $66M | -76.3% | -20.3% | -289.0% | |
 TWST | $377M | +19.2% | +33.1% | -36.2% | |
 RXRX | $75M | +56.7% | +85.4% | -867.9% | |
 SDGR | $256M | +4.8% | +18.8% | -65.2% | |
 BEAM | $140M | +163.3% | +466.3% | -274.6% | |
 SEER | $16M | -13.3% | +89.7% | -483.9% |
ABCL Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $75.1M | +160.6% | $46.3M | 61.6% | $-217,103,000 | -289.0% |
| 2024 | $28.8M | -24.2% | $28.8M | 100.0% | $-314,766,000 | -1091.7% |
| 2023 | $38.0M | -92.2% | $38.0M | 100.0% | $-237,207,000 | -623.8% |
| 2022 | $485.4M | +29.4% | $419.0M | 86.3% | $216.5M | 44.6% |
| 2021 | $375.2M | +60.9% | $329.7M | 87.9% | $204.4M | 54.5% |
| 2020 | $233.2M | +1907.9% | $206.0M | 88.4% | $156.0M | 66.9% |
| 2019 | $11.6M | +31.5% | $11.6M | 100.0% | $-4,117,000 | -35.5% |
| 2018 | $8.8M | - | $8.8M | 100.0% | $-753,000 | -8.5% |
ABCL Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABCL — Frequently Asked Questions
Quick answers to the most common questions about buying ABCL stock.
Is ABCL's revenue growth accelerating or slowing?
ABCL revenue is declining -76.3% year-over-year. TTM revenue fell to $66M, contrasting with the 5-year CAGR of -20.3%. The reversal reflects either macro headwinds or company-specific challenges.
What is ABCL's revenue history from 2018 to 2026?
AbCellera Biologics Inc. (ABCL) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $66M, growing at -76.3% YoY. The 5-year CAGR is -20.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ABCL's long-term revenue growth rate (CAGR)?
AbCellera Biologics Inc.'s 5-year revenue CAGR of -20.3% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -76.3% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ABCL.
Why does ABCL's quarterly revenue fluctuate?
ABCL quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. AbCellera Biologics Inc.'s revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is ABCL's revenue distributed by segment?
ABCL reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ABCL's revenue compare to industry peers?
AbCellera Biologics Inc. (ABCL) with TTM revenue of $66M and -76.3% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.